November 14, 2017:
Further to last week’s communications regarding EpiPen® Jr supply constraints, the following is updated information regarding both EpiPen® Jr and EpiPen® supply.
EpiPen® 300mcg adrenaline (epinephrine) autoinjector: Whilst most Australian pharmacies should currently have a limited supply of EpiPen® 300mcg adrenaline (epinephrine) autoinjectors, if a pharmacy is out of stock they should contact Mylan Australia Customer Support team on 1800 274 276, to ensure that patients requiring EpiPen® 300mcg are supplied. Please refer to the attached letter for the official notification from Mylan Australia. Mylan Australia expects normal supply of EpiPen® 300mcg through their wholesaler network to recommence in late November 2017.
EpiPen® Jr 150mcg adrenaline (epinephrine) autoinjector: As communicated last week, Mylan Australia is experiencing a temporary, limited supply of EpiPen® Jr 150mcg adrenaline (epinephrine) autoinjectors and is supplying eligible patients with an EpiPen® Jr, expiring on 30 November 2017, at no charge. Patients can obtain supply by contacting their pharmacy. Pharmacists should then contact the Mylan Customer Support team on 1800 274 276 to request an EpiPen® Jr (expiring 30 November 2017), that will be supplied to the pharmacy and patient at no charge. Patients will need to return to their pharmacy with their prescription to replace the EpiPen® Jr at the end of November. Mylan Australia expects normal supply of EpiPen® Jr 150mcg through their wholesaler network to recommence in late November 2017.
Please note that New Zealand is not affected by these temporary supply issues.
ASCIA recommends EpiPen® Jr 150mcg for patients weighing between 10-20kgs and EpiPen® 300mcg for patients 20kgs and over.